Literature DB >> 6686533

Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy.

B J Maron, S E Epstein, A G Morrow.   

Abstract

Since 1960, at the National Institutes of Health, ventricular septal myotomy and myectomy has been the mode of treatment for severely symptomatic patients with hypertrophic cardiomyopathy and obstruction to left ventricular outflow who do not respond to medical therapy. Our long-term results of operation for hypertrophic cardiomyopathy are reviewed in 240 patients operated upon prior to 1980. Postoperatively, most patients had improved symptomatically (i.e. 70%) and manifested marked reduction or abolition of the basal left ventricular outflow gradient (i.e. 98%). However, 8% of the patients died of causes related to operation, 9% had persistent or recurrent severe functional limitation, and 7% died up to 19 years postoperatively due to the underlying cardiomyopathy. Of 17 late postoperative deaths, eight were sudden and nine were due to chronic heart failure. In particular, postoperative atrial fibrillation was a significant contributing factor to poor clinical outcome. Hence, while ventricular septal myotomy-myectomy is not always a curative procedure for obstructive hypertrophic cardiomyopathy, the vast majority of patients who survive operation experience long-lasting clinical improvement.

Entities:  

Mesh:

Year:  1983        PMID: 6686533     DOI: 10.1093/eurheartj/4.suppl_f.175

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

1.  [Transcoronary ablation of septal hypertrophy (TASH): supersedes it the surgery (myectomy)?].

Authors:  H Kuhn; F Gietzen
Journal:  Herz       Date:  1999-12       Impact factor: 1.443

2.  Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.

Authors:  Amelie Burghardt; Frank van Buuren; Zisis Dimitriadis; Tim Grübbel; Hubert Seggewiss; Smita Scholtz; Dieter Horstkotte; Lothar Faber
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

Review 3.  Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy.

Authors:  J M Criley; R J Siegel
Journal:  Postgrad Med J       Date:  1986-06       Impact factor: 2.401

Review 4.  Transaortic septal myectomy: techniques and pitfalls.

Authors:  Anthony Ralph-Edwards; Rachel D Vanderlaan; Pietro Bajona
Journal:  Ann Cardiothorac Surg       Date:  2017-07

5.  Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; F Cecchi; W J McKenna
Journal:  Br Heart J       Date:  1994-12

6.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

7.  Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.

Authors:  F H Gietzen; C J Leuner; L Obergassel; C Strunk-Mueller; H Kuhn
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

8.  Progression of hypertrophic cardiomyopathy. A cross sectional echocardiographic study.

Authors:  S Domenicucci; E Lazzeroni; J Roelandt; F J ten Cate; W B Vletter; A C Arntzenius; S K Das
Journal:  Br Heart J       Date:  1985-04

9.  Unique cause of right hemispheric syndrome: Embolism of myocardium after open septal myectomy.

Authors:  Meghan E Murphy; Giuseppe Lanzino; Aditya Raghunathan; Hartzell Schaff; Jennifer E Fugate
Journal:  Neuroradiol J       Date:  2016-02-02

Review 10.  Percutaneous transluminal septal myocardial ablation.

Authors:  D N Rubin; E M Tuzcu; H M Lever
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.